Most importantly, while C9orf72 transcript levels seem to be reduced by approximately 50%, protein levels are probably reduced by only 25% and there is no indication that C9orf72 functionality is impaired in C9 ALS/FTD patients. This evidence concerns the gene C9 and frontotemporal dementia.